Risk-adaptive cardio-oncology rehabilitation moves exercise into cancer care pathways
Cardiovascular toxicity can narrow the therapeutic window in cancer care. When a patient begins chemotherapy, targeted therapy, radiation, or combined treatment with limited cardiac reserve, the consequences reach beyond the heart: treatment tolerance falls, fatigue deepens, functional recovery slows, and survivorship becomes harder to preserve. A new narrative review in Healthcare recasts cardio-oncology rehabilitation as a clinical framework rather than a simple exercise recommendation, arguing for individualized prescribing, multimodal monitoring, and reassessment tied to meaningful changes in status.
The review was built on a broad search of PubMed/MEDLINE and the Web of Science Core Collection through 27 July 2026. Rather than pooling results in a meta-analysis, the authors organized the literature into direct clinical evidence, guidance and synthesis, feasibility and implementation studies, and mechanistic or conceptual sources. That choice matters because the field still sits between proof and practice: enough data support movement-based care to justify clinical use in selected patients, but not enough exists to make a single universal program look safe, effective, or appropriate for every cancer trajectory.
Exercise prescription depends on treatment context, symptoms, and stability
Evidence across clinical studies supports gains in cardiorespiratory fitness, selected cardiovascular risk factors, and some functional outcomes. Those gains are clinically meaningful because they translate into better reserve during therapy, better recovery between treatment cycles, and greater likelihood that patients can stay active during survivorship. Yet the same evidence base remains uneven. Direct data are dominated by breast-cancer cohorts and women, while mixed-cancer, lymphoma, and lung-cancer studies extend the picture without fully resolving it.
The exercise prescription emerging from this literature is intentionally flexible. Aerobic and resistance training should be adapted to treatment phase, symptom burden, functional capacity, and clinical stability. A patient with controlled symptoms and adequate reserve can usually tolerate a different program than a patient with deconditioning, anemia, arrhythmia risk, neuropathy, or recent cardiotoxic exposure. In practice, cardio-oncology rehabilitation becomes a moving target: not a static fitness plan, but a dose-adjusted intervention that tracks the physiologic strain of cancer treatment itself.
Some endpoints remain frustratingly unresolved. Effects on cancer therapy-related cardiac dysfunction, cardiovascular events, and mortality are still uncertain. The biological plausibility is strong enough to keep the field moving—exercise can improve hemodynamic efficiency, support endothelial function, preserve skeletal muscle, and blunt deconditioning—but hard cardiovascular outcomes have not yet been settled by the available studies. Until those data arrive, rehabilitation should be viewed as supportive care with measurable functional value, not as a proven strategy to prevent major cardiac events.
Exercise can improve capacity without yet proving protection from cardiotoxicity.
Multimodal monitoring turns rehabilitation into reassessment-driven care
The review places special weight on monitoring because cardio-oncology rehabilitation cannot be delivered safely on exercise prescription alone. Clinical stability must be checked, symptoms must be interpreted in real time, and actionable findings should trigger reassessment rather than automatic progression. Monitoring in this setting is not decorative; it is the safeguard that allows exercise to be individualized rather than improvised.
A multimodal approach fits the biology of cancer treatment. Functional decline may reflect direct myocardial injury, anemia, autonomic disturbance, sarcopenia, inflammation, medication effects, or simple inactivity layered on top of a demanding diagnosis. No single metric captures all of that. Blood pressure, heart rate response, symptom patterns, functional tests, and other clinically relevant observations can be combined to decide whether a patient should advance, hold, modify, or pause rehabilitation. The proposed framework emphasizes actionable findings, which means the exercise dose changes when the body changes.
Artificial intelligence, digital twins, omics, and monitoring-guided exercise-dose adjustment appear in the review as promising but still investigational tools. Their appeal is obvious. Cancer care generates complex, rapidly shifting data, and future systems may be able to integrate treatment exposure, physiologic response, and recovery patterns into a more precise rehabilitation plan. For now, those approaches remain conceptual. They may eventually sharpen dose selection and risk stratification, but they are not yet a substitute for clinical judgment at the bedside.
Implementation is the hardest part of making rehabilitation routine
The review makes a practical argument: cardio-oncology rehabilitation should be linked to guideline-based risk assessment and clinically indicated reassessment. That is a meaningful shift away from a one-size-fits-all exercise referral. The real barrier is not whether movement helps, but how to deliver it across different treatment settings, patient preferences, comorbidity profiles, and access constraints.
Implementation will determine whether this framework stays academic or becomes routine care. Adults with cancer often move through fragmented systems, and rehabilitation may fall between oncology, cardiology, physiotherapy, and survivorship services. A risk-adaptive pathway can only work if teams know when to refer, what to monitor, how to respond to deterioration, and how to coordinate across disciplines. The review explicitly calls for prospective studies that test therapy-specific timing, risk-stratified delivery, monitoring-guided dose adjustment, clinical endpoints, equity, and cost-effectiveness.
That list is the real agenda. Timing needs to be matched to cancer therapy, not assumed to be universal. Risk stratification needs to determine who can safely enter rehabilitation and who requires closer oversight. Equity matters because the evidence base is still concentrated in selected populations, especially women with breast cancer, while many other cancer groups remain underrepresented. Cost-effectiveness will decide whether programs can be scaled beyond specialized centers.
What this review changes for clinicians
For clinicians, the clearest message is that cardio-oncology rehabilitation should be treated as exercise-centered care linked to formal cardiovascular risk assessment. It is not a cosmetic add-on to oncology treatment. It is a structured recovery strategy for patients whose cardiovascular reserve, treatment tolerance, or post-treatment function is threatened by cancer therapy or pre-existing disease.
The framework is useful because it avoids overclaiming. It does not promise that exercise will eliminate cardiotoxicity or prevent every adverse cardiovascular outcome. Instead, it positions rehabilitation where the evidence is strongest: improving fitness, supporting function, and helping patients remain stable enough to continue treatment and recovery. The conceptual pathway also makes clear where the evidence remains thin. There is no validated universal model yet, and the proposed risk-adaptive structure still needs prospective testing before it can be treated as standard of care.
Until then, the most defensible approach is individualized care. Use exercise, but dose it to the patient. Monitor, but only for findings that change management. Reassess when clinical status shifts. The field is moving toward more precise rehabilitation, but the next step is not more enthusiasm; it is better prospective evidence showing who benefits, when they benefit, and at what cost.